Investigational drug · Phase 2
rapcabtagene autoleucel
Also called: YTB323
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
9
Any phase or sponsor naming "rapcabtagene autoleucel"
First trial start
2023
Feb 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rapcabtagene autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Nephritis
- Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
- ANCA Associated Vasculitis (AAV)
- Scleroderma, Diffuse
- Idiopathic Inflammatory Myopathies
- Progressive Multiple Sclerosis
- Relapsing Multiple Sclerosis
- Lupus Erythematosus, Systemic
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Multiple sclerosis · Rheumatoid arthritis · Lupus (SLE) · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "rapcabtagene autoleucel" as an intervention, largest first.
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03960840 · 218 participants · Start Jun 26, 2019 · Primary completion Jun 30, 2027
Drug: Rapcabtagene autoleucel single agent; Ibrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma and 2 more
Sites: Los Angeles, California; Stanford, California; Tampa, Florida · 37 sites in all
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06581198 · 179 participants (planned) · Start Sep 4, 2024 · Primary completion Feb 14, 2028
Drug: rapcabtagene autoleucel · For: Lupus Erythematosus, Systemic; Lupus Nephritis
Sites: Birmingham, Alabama; San Bernardino, California; San Francisco, California · 107 sites in all
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06868290 · 126 participants (planned) · Start Mar 13, 2025 · Primary completion Jun 7, 2029
Drug: Rapcabtagene autoleucel; Glucocorticoids · For: ANCA Associated Vasculitis (AAV)
Sites: Aurora, Colorado; Jacksonville, Florida; Chicago, Illinois · 39 sites in all
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06655896 · 96 participants (planned) · Start Oct 29, 2024 · Primary completion Nov 30, 2028
Drug: rapcabtagene autoleucel; rituximab · For: Scleroderma, Diffuse
Sites: Los Angeles, California; San Francisco, California; San Pablo, California · 93 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06675864 · 28 participants (planned) · Start Dec 12, 2024 · Primary completion Jun 14, 2030
Drug: rapcabtagene autoleucel (YTB323) · For: Progressive Multiple Sclerosis
Sites: Darlinghurst, Australia; Melbourne, Australia; Québec, Canada · 18 sites in all
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple SclerosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06617793 · 28 participants (planned) · Start Feb 24, 2025 · Primary completion Aug 7, 2030
Drug: rapcabtagene autoleucel (YTB323) · For: Relapsing Multiple Sclerosis
Sites: Darlinghurst, Australia; Melbourne, Australia; Montpellier, France · 18 sites in all
- A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07048197 · 27 participants (planned) · Start Jun 20, 2025 · Primary completion Nov 1, 2028
Drug: Rapcabtagene autoleucel · For: Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Sites: Bordeaux, France; Brest, France; Le Kremlin-Bicêtre, France · 12 sites in all
- Phase 2 Study of Rapcabtagene Autoleucel in MyositisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06665256 · 21 participants · Start Dec 17, 2024 · Primary completion Mar 9, 2029
Drug: Rapcabtagene autoleucel · For: Idiopathic Inflammatory Myopathies
Sites: Birmingham, Alabama; Zephyrhills, Florida; Augusta, Georgia · 68 sites in all
Stanford UniversityAcademic, hospital or other
NCT07443137 · 20 participants (planned) · Start Sep 15, 2026 · Primary completion Aug 2028
Drug: Rapcabtagene autoleucel (YTB323) · For: Large-cell Lymphoma
Sites: Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas.
Wang M · Cancer Discov 2023
- A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Dickinson MJ, Barba P, Jäger U, et al. · Cancer Discov 2023
Also in development for Lupus Nephritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- IPG11406Phase 23 trials
Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.